Our study may contribute to clarifying how 4-1BB signal modulates T cells in vivo, and thus addressing potential efficacy and safety issues in agonistic 4-1BB antibody-based cancer immunotherapeutics that we are actively pursuing. This evidence concerns the gene TNFRSF9 and cancer.